Advances in gene therapy and immunotherapy for brain tumors

Current Opinion in Neurology

Volumn 16, Issue 6, 2003, Pages 665-670

  Kew, Yvonne ^a   Levin, Victor A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Gene therapy; Glioma; Vaccine

Indexed keywords

ACICLOVIR; BACTERIAL VACCINE; CARCINOEMBRYONIC ANTIGEN; CYTOKINE; E1A PROTEIN; E1B PROTEIN; GANCICLOVIR; IMMUNOGLOBULIN G; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; ONCOLYTIC VIRUS; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RETINOBLASTOMA PROTEIN; THYMIDINE KINASE; TUMOR VACCINE; VIRUS VACCINE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER IMMUNOTHERAPY; DENDRITIC CELL; GENE THERAPY; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; IMMUNE RESPONSE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NONHUMAN; RECOMBINANT DNA TECHNOLOGY; REVIEW; SUICIDE GENE THERAPY; T LYMPHOCYTE; TRANSGENE; TUMOR SUPPRESSOR GENE;

BRAIN NEOPLASMS; CANCER VACCINES; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL;

EID: 1842454112     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200312000-00004     Document Type: Review

References (34)

1. Berger MS, Leibel SA, Bruner JM, et al. Primary central nervous system tumors of the supratentorial compartment. In: Levin VA, editor. Cancer in the nervous system. 2nd ed. New York: Oxford University Press; 2002. pp. 75-236.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
3. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001; 15:1311-1333.
4. Basso U, Ermani M, Vastola F, Brandes AA. Non-cytotoxic therapies for malignant gliomas. J Neurooncol 2002; 58:57-69. This is an easy-to-read review that summarizes innovative treatments.
5. Castro MG, Cowen R, Williamson IK, et al. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003; 98:71-108. This article, which is similar to a book chapter in its comprehensiveness, presents various brain tumor treatments.
6. Hao C, Parney IF, Roa WH, et al. Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation. Acta Neuropathol (Berl) 2002; 103:171-178. This article introduces and covers glioma immunology in a very helpful fashion.
7. Yang L, Ng KY, Lillehei KO. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 2003; 10:138-147. This review updates recent immunotherapeutic approaches for the treatment of malignant glioma.
8. Ostergaard L, Hochberg FH, Rabinov JD, et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg 1999; 90:300-305.
9. Heiss JD, Papavassiliou E, Merrill MJ, et al. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 1996; 98:1400-1408.
10. Benedetti S, Pirola B, Poliani PL, et al. Dexamethasone inhibits the anti-tumor effect of interleukin 4 on rat experimental gliomas. Gene Ther 2003; 10:188-192. This article indicates drug-drug interactions that can limit the usefulness of a novel immunotherapeutic treatment.
11. Liau LM, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999; 90:1115-1124.
12. Witham TF, Erff ML, Okada H, et al. 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery 2002; 50:1327-1334; discussion 1334-1335. This report is very helpful in suggesting alternative methods of deriving tumor antigens for dendritic cells, described in the information given for designing vaccines.
13. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61:842-847.
14. Kikuchi T, Akasaki Y, Irie M, et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 2001; 50:337-344.
15. Kikuchi T, Akasaki Y, Abe T, Ohno T. Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol Immunother 2002; 51:424-430. These findings are particularly interesting, in that the novel vaccine reported was more effective when delivered via intracranial injections rather than subcutaneously.
16. Sioud M, Sorensen D. Generation of an effective anti-tumor immunity after immunization with xenogeneic antigens. Eur J Immunol 2003; 33:38-45. The authors discuss the efficacy of utlizing the immune response, introducing basic immunological concepts of foreign antigens and cross-reactivity.
17. Lumniczky K, Desaknai S, Mangel L, et al. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model. Cancer Gene Ther 2002; 9:44-52. This paper screens a wide panel of cytokines to determine which are immunogenic, corroborating information given in previous studies.
18. Burton A. New glioma vaccine in pipeline. Lancet Oncol 2002; 3:327. This very brief news report previews the preliminary results for a novel bacterial vaccine design.
19. Culver KW, Ram Z, Wallbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256:1550-1552.
20. Freeman SM, Abboud CN, Whartenby KA, et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53:5274-5283.
21. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11:2389-2401.
22. Wiewrodt R, Amin K, Kiefer M, et al. Adenovirus-mediated gene transfer of enhanced herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther 2003; 10:353-364. The group previously generated new and improved mutant thymidine kinases, which are now seen as having greater efficacy in in-vivo targeted tumor cell killing.
23. Desaknai S, Lumniczky K, Esik O, et al. Local tumour irradiation enhances the anti-tumour effect of a double-suicide gene therapy system in a murine glioma model. J Gene Med 2003; 5:377-385. A recent publication shows enhanced tumor killing in vivo by using two suicide genes in a single construct.
24. Lv SQ, Yang H, He JQ, et al. Effects of CD/5-FC suicide gene therapy system on human malignant glioma cells in vitro. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2003; 35:430-434.
25. Aghi M, Kramm CM, Chou TC, et al. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998; 90:370-380.
26. Maeda M, Moriuchi S, Sano A, Yoshimine T. New drug delivery system for water-soluble drugs using silicone and its usefulness for local treatment: application of GCV-silicone to GCV/HSV-tk gene therapy for brain tumor. J Control Release 2002; 84:15-25. This paper reports on a recent formulation of silicone, which has been used in various drug systems, and demonstrates enhanced local delivery of gancyclovir with limited systemic contamination.
27. Miura F, Moriuchi S, Maeda M, et al. Sustained release of low-dose ganciclovir from a silicone formulation prolonged the survival of rats with gliosarcomas under herpes simplex virus thymidine kinase suicide gene therapy. Gene Ther 2002; 9:1653-1658. This study demonstrates the sustained release of a silicone drug preparation that led to better survival in a brain tumor animal model.
28. Lamfers ML, Grill J, Dirven CM, et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002; 62:5736-5742. This report presents the synergistic killing of tumor cells using conditionally replication competent adenovirus with irradiation.
29. Fueyo J, Alemany R, Gomez-Manzano C, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003; 95:652-660. This study reports the characterization of the activity of a conditionally replicative competent adenovirus with altered RGD-4C, which enhances infection in heterogenous coxsackie-adenovirus receptor-expressing tumor cells without compromising specificity.
30. Grill J, Van Beusechem VW, Van Der Valk P, et al. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin Cancer Res 2001; 7:641-650.
31. Suzuki K, Fueyo J, Krasnykh V, et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001; 7:120-126.
32. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72:9706-9713.
33. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003; 10:292-303. This study describes the isolation of a clinically derived infectious herpes strain with modifications to generate a stronger oncolytic virus able to induce an immune response.
34. Phuong LK, Allen C, Peng KW, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003; 63:2462-2469. This report features a novel tumor vaccine that was effective in animal models. The vaccine was generated from a strain of measles virus with a blood serum marker inserted to monitor viral replication in vivo.